Supplemental HIV Testing Market Woes Force FDA To Consider Other Options
This article was originally published in The Gray Sheet
Executive Summary
The financial instability of Calypte Biomedical over the past several months has increased FDA's interest in licensing alternative approaches for confirmatory HIV testing for blood banks, including nucleic acid testing